hapabapa/iStock Editorial via Getty Images
- AbbVie said it is lowering its Q1 and fiscal 2025 EPS guidance due to acquired IPR&D and milestones expense.
- Those expenses will result in a $248M impact on a pre-tax basis, representing a negative impact of $0.13 to both GAAP diluted earnings per